Loading
Rare cancers often share a broken cellular machine even when they arise in different organs. Grouping patients by that shared fault makes trials possible.
Tumour-agnostic approvals so far follow single alterations such as NTRK fusions or mismatch repair deficiency. Many rare cancers instead share mechanism classes (SWI/SNF complex loss including SMARCB1 and SMARCA4, chromatin regulator loss, fusion-driven transcription factor addiction, metabolic enzyme mutations) that could define baskets with dozens of contributing diagnoses and a common therapeutic hypothesis such as EZH2 or PRMT5 dependence.
One of the most cited reviews Europe PMC returns for EZH2 in Sarcomas, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for EZH2 in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and twelve idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for EZH2 in Sarcomas, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma, Synthetic lethality, Synthetic lethality approaches, CRISPR functional genomics.
Shares Synthetic lethality, Synthetic lethality approaches, CRISPR functional genomics, Tumour heterogeneity and clonal evolution.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Tumour-agnostic (tissue-agnostic) approval, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
Shares Synthetic lethality, Synthetic lethality approaches, CRISPR functional genomics, Tumour-agnostic (tissue-agnostic) approval.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, DepMap (Cancer Dependency Map), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares DepMap (Cancer Dependency Map), Synthetic lethality, Synthetic lethality approaches, CRISPR functional genomics.
Shares Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial), NCI-COG Pediatric MATCH (APEC1621), EZH2, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Trial design, endpoints and cost, Sarcomas (soft tissue, bone, GIST).